Key result
Screening of 699 serum samples found that while 6.6% initially tested positive for SV40 antibodies, none were confirmed as authentic, indicating no serologic evidence of prevalent SV40 infection.
Why the study?
Is there serologic evidence of prevalent simian virus 40 (SV40) infection in humans?
Population
699 human subjects, comprising normal control subjects, patients with osteosarcoma, and patients with…
Design
Case-control
Authors
Loading...
No confirmed SV40 antibodies in 699 samples; supports absence of prevalent human infection and cross-reactivity with BKV/JCV.
Case-Control (n=699)
Is there serologic evidence of prevalent simian virus 40 (SV40) infection in humans?
There is no serologic evidence to support the hypothesis that SV40 is a prevalent human pathogen, as apparent SV40 reactivity is due to cross-reactivity with BKV and/or JCV antibodies.
Carter et al. (2003) conducted a case-control in Osteosarcoma or prostate cancer (n=699). SV40 infection vs. Normal controls was evaluated on Prevalence of SV40 antibodies. Screening of 699 serum samples found that while 6.6% initially tested positive for SV40 antibodies, none were confirmed as authentic, indicating no serologic evidence of prevalent SV40 infection.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: